Cipla bidding for Belgian drug maker

Initially, Lupin and Torrent Pharma were also contending for the bid, but dropped out later

acquisition-760x415

(Photo Courtesy: www.customerexperiencereport.com)

An acquisition which is pegged at $1.3 billion, Indian drug maker Cipla is eying Kremers Urban, the specialty generics drug business of the US $4 billion Belgian drug maker UCB.

Initially, Lupin and Torrent Pharma were also contending for the bid, but dropped out later.

Kremers sales revenue stood at $463 million for 2014.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X